Test of sample preparation.

<p>The activity of the PainOmics samples was analysed by centre (points represent the average activity for each patient (<i>n</i> = 4). These data indicate the homogeneity of serum sample preparation for our analyses. The presence of several outliers from different centres suggest some variation exists between patient samples for this marker.</p

Participating centres of the PainOmics study.

<p>Participating centres of the PainOmics study.</p

Schematic representation of the validation of personalized SOPs.

<p>Schematic representation of the validation of personalized SOPs.</p

Chromatogram of 2-AB labeled N-linked glycans released from the plasma proteins and separated by HILIC-UPLC.

<p>The small vertical bars below the 0 level denote the integration area for each peak, and the major chemical structure present in each glycan group (GP1-GP39) is given above each peak. <b><i>Data points represent medium of at least the duplicate for each samples with the P-values (-log10) for the analysis of associations between plasma glycans and LBP diagnosed at the time of blood collection for glycome analysis</i></b>.</p

DNA concentration before and after validation.

<p>DNA concentrations (mean ± SD) of DNA test samples in duplicate. Dots indicate single DNA samples of Clinical Centres before and after SOP adjustment.</p

ROC analysis of normalised Act_A11 activity with PainOmics versus control serum samples.

<p>The Area Under the Curve (AUC) of 0.51 ± 0.06 indicates this marker is essentially invariant between serum controls versus PainOmics samples, thereby confirming the homogeneity of the various samples received.</p

Test of sample integrity.

<p> Normalised carboxypeptidase activity for PainOmics samples analysed (<i>A</i>) by centre and (<i>B</i>) as a whole PainOmics group versus control serum samples. (Control = 1.0 ± 0.1 versus PainOmics = 1.0 ± 0.2; unpaired t test <i>P</i> = 0.6). Each data point represents an individual patient sample (average of <i>n</i> = 8 replicates).</p

Groups of IgG N-glycans from Table 3 that showed statistically significant difference in observed values (corrected by sex, age, and African admixture) between 101 Afro-Caribbean cases with SLE and 183 controls.

*<p>t-test for equality of means (2-tailed).</p

An analysis of pleiotropy between loci associated with IgG glycans and previously reported disease/trait susceptibility loci, with linkage disequilibrium computed between the most significantly associated SNPs.

<p>Associations are those found in the GWAS Catalog track of USCS Genome browser (accessed 04/07/2012) and LD has been calculated using SNAP (<a href="http://www.broadinstitute.org/mpg/snap/Johnson" target="_blank">http://www.broadinstitute.org/mpg/snap/Johnson</a>, A. D., Handsaker, R. E., Pulit, S., Nizzari, M. M., O'Donnell, C. J., de Bakker, P. I. W. SNAP: A web-based tool for identification and annotation of proxy SNPs using HapMap <i>Bioinformatics, 2008 24(24):2938–2939</i>).</p

Twelve groups of IgG N-glycans (of 77 measured) that showed nominally significant difference (p<0.05) in observed values between 5 mice that were heterozygous <i>Ikzf1</i> knock-outs (Neo) and 5 wild-type controls (wt).

<p>The global difference test was significant (p = 0.03). ^*t-test for equality of means (2-tailed).</p